Trial Profile
A non-interventional observational study in adults assessing the safety and tolerability of AVANZ® in case of concomitant specific immunotherapy (SCIT/AIT/SLIT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Olea pollen allergy immunotherapy (Primary)
- Indications Tree pollen hypersensitivity
- Focus Adverse reactions
- Sponsors ALK-Abello
- 03 Jul 2013 New trial record